Literature DB >> 26120380

Advances of multidetector computed tomography in the characterization and staging of renal cell carcinoma.

Athina C Tsili1, Maria I Argyropoulou1.   

Abstract

Renal cell carcinoma (RCC) accounts for approximately 90%-95% of kidney tumors. With the widespread use of cross-sectional imaging modalities, more than half of RCCs are detected incidentally, often diagnosed at an early stage. This may allow the planning of more conservative treatment strategies. Computed tomography (CT) is considered the examination of choice for the detection and staging of RCC. Multidetector CT (MDCT) with the improvement of spatial resolution and the ability to obtain multiphase imaging, multiplanar and three-dimensional reconstructions in any desired plane brought about further improvement in the evaluation of RCC. Differentiation of RCC from benign renal tumors based on MDCT features is improved. Tumor enhancement characteristics on MDCT have been found closely to correlate with the histologic subtype of RCC, the nuclear grade and the cytogenetic characteristics of clear cell RCC. Important information, including tumor size, localization, and organ involvement, presence and extent of venous thrombus, possible invasion of adjacent organs or lymph nodes, and presence of distant metastases are provided by MDCT examination. The preoperative evaluation of patients with RCC was improved by depicting the presence or absence of renal pseudocapsule and by assessing the possible neoplastic infiltration of the perirenal fat tissue and/or renal sinus fat compartment.

Entities:  

Keywords:  Carcinoma; Computed tomography; Kidney; Multidetector computed tomography; Renal cell carcinoma; Staging

Year:  2015        PMID: 26120380      PMCID: PMC4473304          DOI: 10.4329/wjr.v7.i6.110

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  113 in total

1.  Planning nephron-sparing renal surgery using 3D helical CT angiography.

Authors:  P A Smith; F F Marshall; F M Corl; E K Fishman
Journal:  J Comput Assist Tomogr       Date:  1999 Sep-Oct       Impact factor: 1.826

Review 2.  How not to miss or mischaracterize a renal cell carcinoma: protocols, pearls, and pitfalls.

Authors:  Pamela T Johnson; Karen M Horton; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2010-04       Impact factor: 3.959

3.  Angiomyolipoma with minimal fat and non-clear cell renal cell carcinoma: differentiation on MDCT using classification and regression tree analysis-based algorithm.

Authors:  Sungmin Woo; Jeong Yeon Cho; Seung Hyup Kim; Sang Youn Kim
Journal:  Acta Radiol       Date:  2013-11-20       Impact factor: 1.990

4.  Multiphasic renal CT: comparison of renal mass enhancement during the corticomedullary and nephrographic phases.

Authors:  B A Birnbaum; J E Jacobs; P Ramchandani
Journal:  Radiology       Date:  1996-09       Impact factor: 11.105

5.  Small renal cell carcinoma: pathologic and radiologic correlation.

Authors:  Y Yamashita; M Takahashi; O Watanabe; S Yoshimatsu; S Ueno; S Ishimaru; M Kan; S Takano; N Ninomiya
Journal:  Radiology       Date:  1992-08       Impact factor: 11.105

Review 6.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

7.  Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma.

Authors:  Christian Gratzke; Michael Seitz; Florian Bayrle; Boris Schlenker; Patrick J Bastian; Niko Haseke; Markus Bader; Derya Tilki; Alexander Roosen; Alexander Karl; Oliver Reich; Wael Y Khoder; Stephen Wyler; Christian G Stief; Michael Staehler; Alexander Bachmann
Journal:  BJU Int       Date:  2009-02-23       Impact factor: 5.588

8.  Comparison of radiographic and pathologic sizes of renal tumors.

Authors:  Wei Chen; Linhui Wang; Qing Yang; Bing Liu; Yinghao Sun
Journal:  Int Braz J Urol       Date:  2013 Mar-Apr       Impact factor: 1.541

9.  Renal cell carcinoma: correlation of CT findings with nuclear morphologic grading in 100 tumors.

Authors:  B A Birnbaum; M A Bosniak; G A Krinsky; D Cheng; J Waisman; M M Ambrosino
Journal:  Abdom Imaging       Date:  1994 May-Jun

10.  Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma.

Authors:  Matteo Brunelli; Albino Eccher; Stefano Gobbo; Vincenzo Ficarra; Giacomo Novara; Paolo Cossu-Rocca; Franco Bonetti; Fabio Menestrina; Liang Cheng; John N Eble; Guido Martignoni
Journal:  Mod Pathol       Date:  2007-09-28       Impact factor: 7.842

View more
  11 in total

1.  Prediction models for clear cell renal cell carcinoma ISUP/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT.

Authors:  Dong Han; Yong Yu; Nan Yu; Shan Dang; Hongpei Wu; Ren Jialiang; Taiping He
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

2.  CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma.

Authors:  Natalie L Demirjian; Bino A Varghese; Steven Y Cen; Darryl H Hwang; Manju Aron; Imran Siddiqui; Brandon K K Fields; Xiaomeng Lei; Felix Y Yap; Marielena Rivas; Sharath S Reddy; Haris Zahoor; Derek H Liu; Mihir Desai; Suhn K Rhie; Inderbir S Gill; Vinay Duddalwar
Journal:  Eur Radiol       Date:  2021-11-10       Impact factor: 5.315

3.  [Risk factors of renal sinus invasion in clinical T1 renal cell carcinoma patients undergoing nephrectomy].

Authors:  Z H Sun; X J Huang; J H Dong; Z Liu; Y Yan; C Liu; L L Ma
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-18

Review 4.  Recent advances in imaging techniques of renal masses.

Authors:  Ankita Aggarwal; Chandan J Das; Sanjay Sharma
Journal:  World J Radiol       Date:  2022-06-28

Review 5.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

6.  Relative Computed Tomography (CT) Enhancement Value for the Assessment of Microvascular Architecture in Renal Cell Carcinoma.

Authors:  Ai-Mei Ouyang; Zhao-Long Wei; Xin-You Su; Kun Li; Dong Zhao; De-Xin Yu; Xiang-Xing Ma
Journal:  Med Sci Monit       Date:  2017-07-31

7.  Circ_101341 Deteriorates the Progression of Clear Cell Renal Cell Carcinoma Through the miR- 411/EGLN3 Axis.

Authors:  Yongjun Yue; Jinsheng Cui; Yu Zhao; Shangying Liu; Weixing Niu
Journal:  Cancer Manag Res       Date:  2020-12-31       Impact factor: 3.989

8.  Clinicopathological and radiological significance of the collateral vessels of renal cell carcinoma on preoperative computed tomography.

Authors:  Xueling Suo; Junru Chen; Yijun Zhao; Qidun Tang; Xibiao Yang; Yuan Yuan; Ling Nie; Ni Chen; Hao Zeng; Jin Yao
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

9.  Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China.

Authors:  Ning Liu; Feng Qu; Qiancheng Shi; Wenyuan Zhuang; Wenliang Ma; Zhenhao Yang; Jing Sun; Wei Xu; Lihua Zhang; Ruipeng Jia; Linfeng Xu; Xiaozhi Zhao; Xiaogong Li; Gutian Zhang; Hongqian Guo; Dongmei Li; Weidong Gan
Journal:  Ann Surg Oncol       Date:  2020-07-06       Impact factor: 5.344

10.  Clinical versus Pathologic staging of Renal Tumors: Role of Multi-Detector CT Urography.

Authors:  Ahmed I Kamel; Mohamed H Badawy; Hossam Elganzoury; Amr Elkhouly; Khalid Elesaily; S Eldahshan; Mohamed A A Ismail; Mostafa F Elshafie; Emam M Abdel Aziz; Ahmed G El Baz; Mamdouh A Roshdy; Tarek R El Leithy; Samir Ghobashy; Ahmed M Kamal
Journal:  Electron Physician       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.